Puma Biotechnology Inc

Company Profile

Puma Biotechnology Inc had its IPO on 2012-04-24 under the ticker symbol PBYI.

The company operates in the Healthcare sector and Biotechnology industry. Puma Biotechnology Inc has a staff strength of 192 employees.

Stock update

Shares of Puma Biotechnology Inc opened at $3.42 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $3.34 - $3.46, and closed at $3.36.

This is a -0.89% slip from the previous day's closing price.

A total volume of 92,604 shares were traded at the close of the day’s session.

In the last one week, shares of Puma Biotechnology Inc have slipped by -9.19%.

Puma Biotechnology Inc's Key Ratios

Puma Biotechnology Inc has a market cap of $161.06 million, indicating a price to book ratio of 9.0642 and a price to sales ratio of 1.0452.

In the last 12-months Puma Biotechnology Inc’s revenue was $230.12 million with a gross profit of $172.94 million and an EBITDA of $38.42 million. The EBITDA ratio measures Puma Biotechnology Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Puma Biotechnology Inc’s operating margin was 12.46% while its return on assets stood at 9.09% with a return of equity of -9.73%.

In Q2, Puma Biotechnology Inc’s quarterly earnings growth was a negative -78.1% while revenue growth was a negative 8.3%.

Puma Biotechnology Inc’s PE and PEG Ratio

Forward PE

11.2867

Trailing PE

0

PEG

0.03

Its diluted EPS in the last 12-months stands at $-0.07 per share while it has a forward price to earnings multiple of 11.2867 and a PEG multiple of 0.03. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Puma Biotechnology Inc’s profitability.

Puma Biotechnology Inc stock is trading at a EV to sales ratio of 1.0921 and a EV to EBITDA ratio of 7.8677. Its price to sales ratio in the trailing 12-months stood at 1.0452.

Puma Biotechnology Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$200.49 million

Total Liabilities

$60.29 million

Operating Cash Flow

$-4683000.00

Capital Expenditure

$68000

Dividend Payout Ratio

0%

Puma Biotechnology Inc ended 2024 with $200.49 million in total assets and $0 in total liabilities. Its intangible assets were valued at $200.49 million while shareholder equity stood at $30.40 million.

Puma Biotechnology Inc ended 2024 with $0 in deferred long-term liabilities, $60.29 million in other current liabilities, 5000.00 in common stock, $-1363228000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $60.01 million and cash and short-term investments were $74.44 million. The company’s total short-term debt was $15,792,000 while long-term debt stood at $87.62 million.

Puma Biotechnology Inc’s total current assets stands at $118.55 million while long-term investments were $0 and short-term investments were $14.43 million. Its net receivables were $31.29 million compared to accounts payable of $7.80 million and inventory worth $7.63 million.

In 2024, Puma Biotechnology Inc's operating cash flow was $-4683000.00 while its capital expenditure stood at $68000.

Comparatively, Puma Biotechnology Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$3.36

52-Week High

$5.16

52-Week Low

$2.08

Analyst Target Price

$4.75

Puma Biotechnology Inc stock is currently trading at $3.36 per share. It touched a 52-week high of $5.16 and a 52-week low of $5.16. Analysts tracking the stock have a 12-month average target price of $4.75.

Its 50-day moving average was $3.53 and 200-day moving average was $3.61 The short ratio stood at 10.2 indicating a short percent outstanding of 0%.

Around 1516.4% of the company’s stock are held by insiders while 5995.5% are held by institutions.